| |  Online-Ressource |
|---|
| Verfasst von: | Sha, Sha [VerfasserIn]  |
|---|
| | Degen, Miriam [VerfasserIn] |
|---|
| | Vlaški, Tomislav [VerfasserIn] |
|---|
| | Fan, Ziwen [VerfasserIn] |
|---|
| | Brenner, Hermann [VerfasserIn] |
|---|
| | Schöttker, Ben [VerfasserIn] |
|---|
| Titel: | The safety profile of vitamin D supplements using real-world data from 445,493 participants of the UK biobank |
|---|
| Titelzusatz: | slightly higher hypercalcemia prevalence but neither increased risks of kidney stones nor atherosclerosis |
|---|
| Verf.angabe: | Sha Sha, Miriam Degen, Tomislav Vlaski, Ziwen Fan, Hermann Brenner and Ben Schöttker |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 12 July 2024 |
|---|
| Umfang: | 17 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Gesehen am 15.01.2025 |
|---|
| Titel Quelle: | Enthalten in: Nutrients |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 16(2024), 14, Artikel-ID 2251, Seite 1-17 |
|---|
| ISSN Quelle: | 2072-6643 |
|---|
| Abstract: | Background: Potential calcium-related adverse events of vitamin D supplement use have not been addressed in large-scale, real-world data so far. Methods: Leveraging data from the UK Biobank, encompassing 445,493 individuals aged 40-69, we examined associations of high 25-hydroxyvitamin (25(OH)D) levels ≥ 100 nmol/L and vitamin D supplementation with hypercalcemia (serum calcium > 2.6 mmol/L), kidney stones, and atherosclerosis assessments (pulse wave arterial stiffness index and carotid intima-medial thickness). Regression models were comprehensively adjusted for 49 covariates. Results: Approximately 1.5% of the participants had high 25(OH)D levels, 4.3% regularly used vitamin D supplements, and 20.4% reported regular multivitamin use. At baseline, the hypercalcemia prevalence was 1.6%, and 1.1% was diagnosed with kidney stones during follow-up. High 25(OH)D levels were neither associated with calcium-related adverse events nor atherosclerosis assessments. Vitamin D and multivitamin supplementation were associated with an increased prevalence of hypercalcemia (odds ratios and 95% confidence intervals: 1.46 [1.32-1.62] and 1.11 [1.04-1.18], respectively) but were neither associated with atherosclerosis nor future kidney stones. Conclusions: High 25(OH)D levels observable in routine care were not associated with any adverse outcome. Vitamin D users have a slightly higher prevalence of hypercalcemia, possibly due to co-supplementation with calcium, but without a higher atherosclerosis prevalence or risk of kidney stones. |
|---|
| DOI: | doi:10.3390/nu16142251 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3390/nu16142251 |
|---|
| | kostenfrei: Volltext: https://www.mdpi.com/2072-6643/16/14/2251 |
|---|
| | DOI: https://doi.org/10.3390/nu16142251 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | adverse events |
|---|
| | atherosclerosis |
|---|
| | hypercalcemia |
|---|
| | kidney stone risk |
|---|
| | real-world evidence |
|---|
| | serum 25-hydroxyvitamin D levels |
|---|
| | vitamin D supplementation |
|---|
| K10plus-PPN: | 1914745086 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬The¬ safety profile of vitamin D supplements using real-world data from 445,493 participants of the UK biobank / Sha, Sha [VerfasserIn]; 12 July 2024 (Online-Ressource)
